To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer
Clinical trial NCT02029209 · UNKNOWN
Trial details
- NCT number
- NCT02029209
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2013-12-01
- Primary completion
- 2017-03-01
- Enrollment
- 110
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.